Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study

The authors present a case of a 57-year-old patient with chronic myeloid leukemia who was treated with ponatinib and subsequently treated with dasatinib. The patient showed a major molecular response; however, the BCR-ABL1 signal increased with low ponatinib and dasatinib trough concentrations. Cobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofman, Susan, Touw, Daan J., Span, Bart F. R., Oude Munnink, Thijs H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2023
Materias:
Grand Rounds
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332646/
https://www.ncbi.nlm.nih.gov/pubmed/37253456
http://dx.doi.org/10.1097/FTD.0000000000001103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332646/
https://www.ncbi.nlm.nih.gov/pubmed/37253456
http://dx.doi.org/10.1097/FTD.0000000000001103

Ejemplares similares